Circle Pharma, a Bay Area biotechnology company, has raised $92.5 million in Series E funding, the company announced September 16, 2026. The round was backed by The Column Group, Nextech Invest, RA Capital Management, Euclidean Capital and pharmaceutical giant Eli Lilly and Company, extending a run of substantial financing for the company since its founding in 2012 with seed funding from Pfizer. The raise places Circle Pharma among a wave of biotech companies that closed significant rounds this week, alongside Sling Therapeutics' $123 million Series C and Anew Labs' $290 million inaugural round in China, underscoring continued investor appetite for differentiated drug-discovery platforms even as broader venture markets have grown more selective in 2026.
Circle Pharma's scientific approach centres on macrocyclic therapeutics — a class of drug molecules characterised by large, ring-shaped structures that occupy a distinctive middle ground between small-molecule drugs and larger biologics. Macrocycles have attracted growing pharmaceutical industry interest in recent years because their structure allows them to potentially reach therapeutic targets that have historically been considered difficult or impossible to address with conventional small-molecule drugs, particularly protein-protein interactions implicated in cancer and other serious diseases. Historically, macrocyclic drug development has been constrained by significant synthesis and optimisation challenges, which has kept the modality a comparatively niche area of pharmaceutical research despite its therapeutic promise.
The involvement of Eli Lilly in this round is particularly notable, reflecting continued strategic interest from large pharmaceutical companies in partnering with and financially backing specialised biotech platforms rather than relying solely on internal research and development to fill their drug pipelines. Large pharmaceutical companies have increasingly used corporate venture arms and direct investment as a mechanism to gain early visibility into promising external drug-discovery platforms, often with an eye toward eventual licensing agreements or acquisition opportunities once a platform company's lead candidates advance through clinical development. Eli Lilly's participation alongside established biotech-focused investors such as RA Capital Management, one of the sector's most active and technically sophisticated specialist investors, lends additional credibility to Circle Pharma's scientific progress since its earlier funding rounds.
Having been founded with seed capital from Pfizer in 2012, Circle Pharma's journey through five funding rounds over more than a decade illustrates the extended timelines characteristic of platform biotech companies, which typically require years of foundational research before generating the kind of clinical data that can support later-stage financing rounds at meaningfully higher valuations. The company's ability to attract continued institutional support across multiple funding cycles, including from some of the industry's most selective specialist life-sciences investors, suggests its macrocyclic drug-discovery platform has continued to generate credible scientific progress even as many biotech platform companies from its founding era have either been acquired, pivoted their focus, or struggled to advance beyond earlier-stage research.
The broader financing environment for biotech in 2026 has shown signs of renewed strength after a more challenging period for the sector in prior years, when rising interest rates and a cooling public-market appetite for clinical-stage biotech companies made later-stage private financing considerably harder to secure. This week's cluster of substantial biotech rounds — spanning Circle Pharma's macrocyclic platform, Sling Therapeutics' thyroid eye disease programme and RegCell's immune-tolerance therapies — suggests investors have regained confidence in backing differentiated, scientifically credible platforms, even as the sector overall remains considerably more selective than it was during the venture capital boom of the earlier part of the decade.
With its Series E capital secured, Circle Pharma's next phase will likely focus on advancing its lead macrocyclic candidates further through preclinical and, potentially, early clinical development, a process that will require continued scientific execution to justify the confidence its investor syndicate has placed in the platform. Whether the company's approach to macrocyclic drug design can translate into clinically validated therapies addressing previously undruggable targets remains the central question that will determine whether this round is remembered as a pivotal step toward a genuinely differentiated new therapeutic modality or another well-financed platform company that struggled to bridge the gap between promising chemistry and clinical proof of concept.
Circle Pharma's extended fundraising history also illustrates how patient, specialist biotech capital differs meaningfully from the faster-moving dynamics common in software and consumer technology investing. Where a software startup might expect to move from seed to a growth-stage round within a few years on the strength of user and revenue growth, platform biotech companies routinely require a decade or more of sustained institutional support before generating the clinical validation needed to justify major valuation step-ups or attract strategic partnership interest from large pharmaceutical companies. Circle Pharma's ability to retain the confidence of return investors alongside new entrants like Eli Lilly across this extended timeline suggests its underlying science has continued to clear the rigorous, incremental validation hurdles that specialist life-sciences investors apply at each successive financing round — a far more demanding due-diligence bar than most technology sectors require, and one that helps explain why successful biotech platform companies, once they do reach an inflection point, are often able to raise substantial rounds like this $92.5 million Series E even in a broader venture environment that has grown considerably more selective.
Investors and industry observers will also be watching how Circle Pharma balances continued independent development of its macrocyclic pipeline against the possibility of striking earlier licensing or co-development deals with large pharmaceutical partners such as Eli Lilly, whose participation in this round could plausibly evolve into a more formal collaboration if early clinical signals prove encouraging. Such arrangements are common in biotech, allowing platform companies to access the marketing, manufacturing and regulatory expertise of an established pharmaceutical partner while retaining meaningful economic upside from any resulting approved therapies, and would represent a natural next milestone for Circle Pharma should its lead macrocyclic candidates continue to advance favourably through development.
Circle Pharma's continued ability to attract new institutional and strategic investors more than a decade after its Pfizer-backed founding also stands as a useful data point for the broader macrocyclic drug-discovery field, lending credibility to a therapeutic modality that many pharmaceutical companies have historically approached with caution given its technical complexity.
